Grundläggande statistik
| LEI | 9695002Y8420ZB8HJE29 |
| CIK | 1598599 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Innate Pharma S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 2, 2025 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF SEPTEMBER 1, 2025 EXHIBIT 99.1 NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF SEPTEMBER 1, 2025 Marseille, France, September 2, 2025, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 2, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday August 4, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Franc |
|
| August 4, 2025 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF AUGUST 1, 2025 EXHIBIT 99.1 NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF AUGUST 1, 2025 Marseille, France, August 4, 2025, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “ |
|
| July 29, 2025 |
INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE EXHIBIT 99.1 INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE Marseille, France, July 29, 2025, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. B |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday July 29, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| July 7, 2025 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 3, 2025 EXHIBIT 99.1 NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 3, 2025 Marseille, France, July 4, 2025, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Comp |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday July 4, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday June 17, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| June 17, 2025 |
EXHIBIT 99.1 INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN H.C. WAINWRIGHT AND WOLFE RESEARCH HEALTHCARE CONFERENCES Marseille, France, June 17, 2025, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed below. • H.C. Wainwright 3rd Annual Imm |
|
| June 13, 2025 |
EXHIBIT 99.1 INNATE PHARMA HIGHLIGHTS PRECLINICAL ANTITUMOR ACTIVITY OF IPH6501 IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS Marseille, France, June 13, 2025, 7:00 AM CEST •Preclinical data from IPH6501, Innate’s proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 13, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 ( |
|
| May 27, 2025 |
INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN JEFFERIES AND GOLDMAN SACHS HEALTHCARE CONFERENCES EXHIBIT 99.1 INNATE PHARMA ANNOUNCES ITS PARTICIPATION IN JEFFERIES AND GOLDMAN SACHS HEALTHCARE CONFERENCES Marseille, France, May 27, 2025, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below. •Jefferies Global Heal |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday May 27, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 23, 2025 |
Outcome of Innate Pharma’s 2025 Annual General Meeting EXHIBIT 99.1 Outcome of Innate Pharma’s 2025 Annual General Meeting Marseille, France, May 23, 2024, 10:00 PM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted. A total of 114 votes were cast out of a |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday May 23, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 23, 2025 |
INNATE PHARMA HIGHLIGHTS DURABLE RESPONSES TO LACUTAMAB IN SEZARY SYNDROME AND MYCOSIS FUNGOIDES EXHIBIT 99.1 INNATE PHARMA HIGHLIGHTS DURABLE RESPONSES TO LACUTAMAB IN SEZARY SYNDROME AND MYCOSIS FUNGOIDES Marseille, France, May 23, 2025, 7:00 AM CEST •Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. •Long-term follow-up data from TELLOMAK study confirms the meaningful clinical activ |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 23, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday May 19, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 19, 2025 |
INNATE PHARMA HIGHLIGHTS ABSTRACTS SELECTED FOR ASCO 2025 ANNUAL MEETING EXHIBIT 99.1 INNATE PHARMA HIGHLIGHTS ABSTRACTS SELECTED FOR ASCO 2025 ANNUAL MEETING Marseille, France, May 19, 2025, 7:00 AM CEST •Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides •Trial in Progress poster on IPH4502, Innate’s differentiated ADC in development in advanced solid tumors expressing Nectin-4 •AstraZeneca to present a poster on updated re |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday May 15, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 15, 2025 |
INNATE PHARMA HIGHLIGHTS ANKET® ABSTRACTS SELECTED FOR THE EHA 2025 CONGRESS EXHIBIT 99.1 INNATE PHARMA HIGHLIGHTS ANKET® ABSTRACTS SELECTED FOR THE EHA 2025 CONGRESS Marseille, France, May 15, 2025, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 13, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 13, 2025 |
INNATE PHARMA REPORTS FIRST QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS EXHIBIT 99.1 INNATE PHARMA REPORTS FIRST QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS Marseille, France, May 13, 2025, 7:00 AM CEST •€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications •First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced so |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Monday May 12, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 12, 2025 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF MAY 5, 2025 EXHIBIT 99.1 NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF MAY 5, 2025 Marseille, France, May 12, 2025, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Compa |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Tuesday May 6, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France |
|
| May 6, 2025 |
INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR Q1 2025 BUSINESS UPDATE EXHIBIT 99.1 INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR Q1 2025 BUSINESS UPDATE Marseille, France, May 6, 2025, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarte |
|
| April 30, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| April 30, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Frederic Lombard, certify that: 1.I have reviewed this annual report on Form 20-F of Innate Pharma S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a |
|
| April 30, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Introduction As of December 31, 2024, Innate Pharma (“Innate,” “we,” “us,” “Company,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Title of Each Class Trading Symbol Name of each exchange on which re |
|
| April 30, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jonathan Dickinson, certify that: 1.I have reviewed this annual report on Form 20-F of Innate Pharma S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday April 30, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Fra |
|
| April 30, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. |
|
| April 30, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement No 333-276164 on Form F-3 and in Registration Statement Nos. |
|
| April 30, 2025 |
AMENDMENT N°. 9 This Amendment No. 9 (the “Amendment”) is made and entered into as of July 18th 2024 (“Effective Date”) between Innate Pharma SA, a corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development, Option and License Agreement dated March 28, 2006, as amended by Amendm |
|
| April 30, 2025 |
TRANSLATION FOR INFORMATION PURPOSES INNATE PHARMA SA A corporation with executive board and supervisory board with a share capital of EUR 4,609,489. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2025 |
EXHIBIT 99.1 INNATE PHARMA FILES ITS 2024 UNIVERSAL REGISTRATION DOCUMENT (DOCUMENT D’ENREGISTREMENT UNIVERSEL) AND 2024 ANNUAL REPORT ON FORM 20-F Marseille, France, April 30, 2025, 5:30 PM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d’enregistrement universel) for the year e |
|
| April 30, 2025 |
MARKET ETHICS CHARTER Relating to the confidentiality of Inside Information and the prevention of insider trading and misconduct within the Innate Pharma Group Updated on April 30, 2025 SUMMARY 1 OBJECTIVES OF THE CHARTER. |
|
| April 29, 2025 |
EXHIBIT 99.1 Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data Of Its Antibody Drug Conjugate IPH4502 At The AACR 2025 Annual Meeting Marseille, France, April 29, 2025, 9:00 PM CEST •IPH4502 is a differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. •IPH4502 demonstrated superior preclinical anti-tumor activity comp |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday April 28, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Fra |
|
| April 28, 2025 |
EXHIBIT 99.1 INNATE PHARMA FILES ITS 2024 UNIVERSAL REGISTRATION DOCUMENT (DOCUMENT D’ENREGISTREMENT UNIVERSEL) AND 2024 ANNUAL REPORT ON FORM 20-F Marseille, France, April 28, 2025, 5:30 PM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Ph |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 24, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 24, 2025 |
Innate Pharma Announces €15m Investment By Sanofi EXHIBIT 99.1 Innate Pharma Announces €15m Investment By Sanofi Marseille, France, April 24, 2025, 7:00 AM CEST •Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET® program in autoimmune indications, and more Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999, |
|
| April 23, 2025 |
EXHIBIT 99.1 Innate Pharma Regains Its Rights On CD123 Targeting ANKET® And Announces Sanofi’s Intention To Make A Strategic Investment In The Company Marseille, France, April 23, 2025, 7:00 AM CEST •Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR’579) /IPH6101 currently in development for AML •Potential investment of up to €15M by Sanofi in Innate Pharma through a capital inc |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 23, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 16, 2025 |
INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MAY 22, 2025 EXHIBIT 99.1 INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MAY 22, 2025 Marseille, France, April 16, 2025, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille. The Notice of Meeting |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 16, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 16, 2025 |
EXHIBIT 99.1 INNATE PHARMA PROPOSES TO ITS SHAREHOLDERS TO TRANSFORM ITS CORPORATE GOVERNANCE STRUCTURE INTO A BOARD OF DIRECTORS AND TO CHANGE ITS COMPOSITION Marseille, France, April 16, 2025, 7:00 AM CEST Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday April 16, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Fra |
|
| April 3, 2025 |
INNATE PHARMA TO PARTICIPATE IN THE 2025 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM EXHIBIT 99.1 INNATE PHARMA TO PARTICIPATE IN THE 2025 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM Marseille, France, April 3, 2025, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025. The exe |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday April 3, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Fran |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 27, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 27, 2025 |
Innate Pharma Reports Full Year 2024 Financial Results And Business Update EXHIBIT 99.1 Innate Pharma Reports Full Year 2024 Financial Results And Business Update Marseille, France, March 27, 2025, 7:00 A.M. CET •FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome oNew data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 26, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 26, 2025 |
EXHIBIT 99.1 Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected For The AACR 2025 Annual Meeting Marseille, France, March 26, 2025, 7:00 A.M. CET •IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. •IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and ac |
|
| March 25, 2025 |
Innate Pharma Announces Its Participation In The Life Sciences Van Lanschot Kempen Conference EXHIBIT 99.1 Innate Pharma Announces Its Participation In The Life Sciences Van Lanschot Kempen Conference Marseille, France, March 25, 2025, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below: Life Sciences Van Lanschot Kempe |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday March 25, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, Fra |
|
| March 20, 2025 |
Innate Pharma announces conference call and webcast for full year 2024 financial results EX-99.1 2 exhibit991-250320.htm EX-99.1 EXHIBIT 99.1 Innate Pharma announces conference call and webcast for full year 2024 financial results Marseille, France, March 20, 2025, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following th |
|
| March 20, 2025 |
6-K 1 a6k-iphx2502271.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday March 20, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: Thursday February 27, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| February 27, 2025 |
INNATE PHARMA TO PARTICIPATE IN THE 2025 LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE EXHIBIT 99.1 INNATE PHARMA TO PARTICIPATE IN THE 2025 LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE Marseille, France, February 27, 2025, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on March 10 |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 17, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| February 18, 2025 |
EXHIBIT 99.1 Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome, heavily pretreated, post-mogamulizumab Breakthrough Therapy Designation is intended to accelerate the developme |
|
| January 27, 2025 |
EXHIBIT 99.1 Innate Pharma Announces First Patient Dosed In Phase 1 Study Of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 In Selected Advanced Solid Tumors Marseille, France, January 27, 2025, 7:00 A.M. CET •IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “C |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 27, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 21, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| January 21, 2025 |
INNATE PHARMA ANNOUNCES NECTIN-4 ANTIBODY DRUG CONJUGATE INVESTOR AND ANALYST EVENT IN NEW YORK EXHIBIT 99.1 INNATE PHARMA ANNOUNCES NECTIN-4 ANTIBODY DRUG CONJUGATE INVESTOR AND ANALYST EVENT IN NEW YORK Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Marseille, France, January 21, 2025, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will host an event for institutional investors an |
|
| January 16, 2025 |
6-K 1 a6k-iphx250116.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 16, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 3019 |
|
| January 16, 2025 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2024 EXHIBIT 99.1 NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2024 Marseille, France, January 16, 2025, 7:00 A.M. CET Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 10, 2025 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| January 10, 2025 |
Innate Pharma Announces Transformative Strategy to Accelerate Growth EXHIBIT 99.1 Innate Pharma Announces Transformative Strategy to Accelerate Growth Marseille, France, January 10, 2025, 7:00 A.M. CET •Strategy anchored on early clinical development of proprietary assets with single-agent potential: oDrive innovation with first-in-class ANKET® NK-cell engager Platform oAccelerate development of differentiated Antibody-Drug Conjugates oAdvance current late-stage as |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 20, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| December 20, 2024 |
Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference EXHIBIT 99.1 Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference Marseille, France, December 20, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francis |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 9, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| December 9, 2024 |
EXHIBIT 99.1 Innate Pharma Presents Lacutamab Improved Health-Related Quality Of Life Data At Ash 2024 From TELLOMAK Phase 2 Study In Patients With Cutaneous T Cell Lymphoma Marseille, France, December 9, 2024, 7:00 A.M. CET •Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Innate Pharma SA (Euronext Paris: |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 6, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| December 6, 2024 |
EXHIBIT 99.1 Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma Marseille, France, December 6, 2024, 7:00 A.M. CET •Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) •Patients wit |
|
| December 6, 2024 |
Additional information on the transaction EXHIBIT 99.2 Additional information on the transaction Marseille, France, December 6, 2024, 7:00 A.M. CET Reserved Capital Increase The capital increase reserved to the Institute for Follicular Lymphoma Innovation (IFLI) (the "Reserved Capital Increase") is effected pursuant to and in accordance with the terms and conditions of the delegation granted in the 22nd resolution of the combined general |
|
| December 3, 2024 |
Innate Pharma highlights abstracts selected for the ASH annual meeting 2024 EXHIBIT 99.1 Innate Pharma highlights abstracts selected for the ASH annual meeting 2024 Marseille, France, December 3, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, hav |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 3, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 20, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| November 20, 2024 |
Innate Pharma Releases Its 2025 Financial Calendar EXHIBIT 99.1 Innate Pharma Releases Its 2025 Financial Calendar Marseille, France, November 20, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: •March 27, 2025: Publication of 2024 financial statements •May 13, 2025: Publication of revenue and cash position for 1Q2025 •May 22, 2025: Annual General Shar |
|
| November 19, 2024 |
EXHIBIT 99.1 Innate Pharma Announces Publication In Science Immunology Highlighting Innovative Next-Generation ANKET® IPH6501 Marseille, France, November 19, 2024, 7:00 A.M. CET •IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL •IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a r |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 19, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 13, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| November 13, 2024 |
Innate Pharma Reports Third Quarter 2024 Business Update And Financial Results EXHIBIT 99.1 Innate Pharma Reports Third Quarter 2024 Business Update And Financial Results Marseille, France, November 13, 2024, 7:00 A.M. CET •Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board •Encouraging initial FDA feedback received on lacutamab regulatory pathway •Lacutamab health-related quality of life and translational data to be presented at the upc |
|
| November 8, 2024 |
EXHIBIT 99.1 Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected For The SITC Annual Meeting 2024 Marseille, France, November 8, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) a |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 8, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| November 7, 2024 |
EXHIBIT 99.1 INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER 2024 RESULTS AND BUSINESS UPDATES Marseille, France, November 7, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 7, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 29, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| October 29, 2024 |
INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCES EXHIBIT 99.1 INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCES Marseille, France, October 29, 2024, 7:00 A.M. CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conferences, detailed below. Stifel Healthcare Conference Event dates: Nove |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 14, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 3 |
|
| October 15, 2024 |
EXHIBIT 99.1 Innate Pharma Appoints Jonathan Dickinson As New Chief Executive Officer And Chairman Of The Executive Board Marseille, France, October 14, 2024, 7:00 A.M. CEST •Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma •Current interim CEO and co-founder Hervé Brailly will support the transition Innate Pharma SA (Euronex |
|
| September 30, 2024 |
Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024 EXHIBIT 99.1 Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024 Marseille, France, September 30, 2024, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will co-host with the Icahn School of Medicine at Mount Sinai a scientific symposium entitled “Next Generation Immunotherapy Discoveries”. The symposium will |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 30, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 23, 2024 |
EXHIBIT 99.1 Innate Pharma Announces FDA Clearance Of The IND For IPH4502, A Nectin-4 ADC To Be Developed In Solid Tumors Marseille, France, September 23, 2024, 7:00 A.M. CEST •IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that t |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 23, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 12, 2024 |
Innate Pharma Reports First Half 2024 Business Update And Financial Results EXHIBIT 99.1 Innate Pharma Reports First Half 2024 Business Update And Financial Results Marseille, France, September 12, 2024, 7:00 A.M. CEST •Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 •NK-Cell engager SAR443579/IPH61011 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study oUpdated data |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 12, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 12, 2024 Commission File Number: 001-39084 Innate Pharma SA (Translation of registrant's name into English) Innate Pharma SA 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| September 12, 2024 |
INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2024 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,049,171.60 euros composed of 80,969,357 ordinary shares, and 14,075 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Compan |
|
| September 11, 2024 |
The below is a free translation prepared by the Company. This document is being provided to you for information purposes only. In case of any inconsistency between the below and the French version of the Terms and Conditions, the latter shall prevail. INNATE PHARMA French société anonyme organized with a Supervisory Board and an Executive Board Share capital of 4,049,171.60 euros Headquarters: 117 |
|
| September 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Innate Pharma S. |
|
| September 11, 2024 |
INNATE PHARMA S.A. French société anonyme organized with a Supervisory Board and an Executive Board With a share capital of EUR 4,049,171.60 Registered office: 117, Avenue de Luminy 13009 Marseille France THE TERMS AND CONDITIONS OF THE 2024 STOCK OPTION PLAN US Salaried Directors & Officers By decision of the Executive Board dated September 11, 2024 1Framework of the allocation of grant of stock |
|
| September 11, 2024 |
The below is a free translation prepared by the Company. This document is being provided to you for information purposes only. In case of any inconsistency between the below and the French version of the Terms and Conditions, the latter shall prevail. INNATE PHARMA A limited liability company in société anonyme form, with an Executive Board and Supervisory Board, with share capital of 4,049,171.60 |
|
| September 11, 2024 |
As filed with the Securities and Exchange Commission on September 11, 2024 As filed with the Securities and Exchange Commission on September 11, 2024 Registration No. |
|
| September 11, 2024 |
TRANSLATION FOR INFORMATION PURPOSES INNATE PHARMA SA A corporation with executive board and supervisory board with a share capital of EUR 4,049,171. |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 9, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 9, 2024 |
Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024 EXHIBIT 99.1 Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024 Marseille, France, September 9, 2024, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study during th |
|
| September 5, 2024 |
EXHIBIT 99.1 Innate Pharma announces conference call and webcast for first half 2024 financial results and business update Marseille, France, September 5, 2024, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update o |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 5, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 4, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| September 4, 2024 |
EXHIBIT 99.1 Innate Pharma announces its participation in the H.C. Wainwright 26th annual global investment conference Marseille, France, September 4, 2024, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming investor conference, detailed below. H.C. Wainwr |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 25, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 ( |
|
| July 25, 2024 |
Number of shares and voting rights of Innate Pharma as of July 10, 2024 EXHIBIT 99.1 Number of shares and voting rights of Innate Pharma as of July 10, 2024 Marseille, France, July 25, 2024, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Co |
|
| June 18, 2024 |
Number of shares and voting rights of Innate Pharma as of June 10, 2024 EXHIBIT 99.1 Number of shares and voting rights of Innate Pharma as of June 10, 2024 Marseille, France, June 18, 2024, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Co |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 18, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 ( |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 17, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 ( |
|
| June 17, 2024 |
EXHIBIT 99.1 Innate Pharma Shares Updated Results From The Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial Marseille, France, June 17, 2024, 7:00 AM CEST •SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-A |
|
| June 4, 2024 |
EXHIBIT 99.1 Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides Marseille, France, June 4, 2024, 7:00 AM CEST •In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent wit |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 4, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 28, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 28, 2024 |
Innate Pharma announces its participation in upcoming investor conferences EXHIBIT 99.1 Innate Pharma announces its participation in upcoming investor conferences Marseille, France, May 28, 2024, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé Brailly, Chief Executive Officer, |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 24, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 24, 2024 |
Innate Pharma Highlights Abstracts Selected For ASCO 2024 Annual Meeting EXHIBIT 99.1 Innate Pharma Highlights Abstracts Selected For ASCO 2024 Annual Meeting Marseille, France, May 24, 2024, 7:00 AM CEST •Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab •Two posters on IPH6501, Innate’s second generation ANKET®, for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma •Ast |
|
| May 23, 2024 |
Outcome of Innate Pharma’s 2024 Annual General Meeting EXHIBIT 99.1 Outcome of Innate Pharma’s 2024 Annual General Meeting Marseille, France, May 23, 2024, 10:00 PM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 23, 2024, in Marseille. All resolutions were voted. A total of 84 votes were cast out of a t |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 23, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 15, 2024 |
Innate Pharma Highlights Abstracts Selected For EHA 2024 Congress EXHIBIT 99.1 Innate Pharma Highlights Abstracts Selected For EHA 2024 Congress Marseille, France, May 15, 2024, 7:00 AM CEST •Two abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer •Two abstracts on IPH6501, Innate’s second generation ANKET® for the treatment of relapsed or refracto |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 15, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 14, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0 |
|
| May 14, 2024 |
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results EXHIBIT 99.1 Innate Pharma Reports First Quarter 2024 Business Update And Financial Results Marseille, France, May 14, 2024, 7:00 AM CEST •First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 •Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers •Five ASCO Annual Meeting 2024 a |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 7, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0) |
|
| May 7, 2024 |
Innate Pharma announces conference call and webcast for Q1 2024 business update EXHIBIT 99.1 Innate Pharma announces conference call and webcast for Q1 2024 business update Marseille, France, May 7, 2024, 7:00 A.M. CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarte |
|
| April 15, 2024 |
EXHIBIT 99.1 Innate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 / Iph6101 Progressing To Phase 2 For Blood Cancer Patients Marseille, France, April 15, 2024, 7:00 AM CEST • Partner Sanofi advances SAR443579 / IPH6101, ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers • Dosing of the first pat |
|
| April 15, 2024 |
Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024 EXHIBIT 99.1 Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024 Marseille, France, April 15, 2024, 7:00 AM CEST Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de Luminy, F-13009 Marseille. The Notice of Meeti |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 15, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 15, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 10, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| April 10, 2024 |
EXHIBIT 99.1 Innate Pharma Presents at AACR 2024 Preclinical Efficacy of its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate Marseille, France, April 10, 2024, 7:00 AM CEST • IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 • In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows |
|
| April 4, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. |
|
| April 4, 2024 |
CONFIDENTIAL Execution Copy Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private and confidential. |
|
| April 4, 2024 |
TRANSLATION FOR INFORMATION PURPOSES INNATE PHARMA SA A corporation with executive board and supervisory board with a share capital of EUR 4 043 732,65 Registered Office: 117, avenue de Luminy, 13009 Marseille 424 365 336 Registry of Trade and Companies of Marseille ARTICLES OF ASSOCIATION (BY-LAWS) Amended by the Executive Board of January 2nd, 2024 TRANSLATION FOR INFORMATION PURPOSES TITLE I FORM – NAME – REGISTERED OFFICE – OBJECT - DURATION ARTICLE 1 - Form The Company was incorporated in the form of a Simplified Share Company governed by applicable statutory provisions and by these articles of association. |
|
| April 4, 2024 |
PG-15109 V1.0 INNATE PHARMA S.A. NASDAQ EXECUTIVE COMPENSATION CLAWBACK POLICY Approved by the Supervisory Board on October 13th 2023 1PURPOSE 9.1The purpose of this policy (this “Clawback Policy”) is to set out the basis for the mandatory recovery of erroneously awarded Incentive-Based Compensation (as defined below) from Executives (as defined below) of Innate Pharma S.A. (the “Company”, togethe |
|
| April 4, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Hervé Brailly, certify that: 1.I have reviewed this annual report on Form 20-F of Innate Pharma S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a ma |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 4, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Introduction As of December 31, 2023, Innate Pharma (“Innate,” “we,” “us,” “Company,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Title of Each Class Trading Symbol Name of each exchange on which re |
|
| April 4, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Frederic Lombard, certify that: 1.I have reviewed this annual report on Form 20-F of Innate Pharma S.A. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a |
|
| April 4, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| March 21, 2024 |
Summary of Consolidated Financial Statements and Notes as of December 31, 2023 EXHIBIT 99.1 Summary of Consolidated Financial Statements and Notes as of December 31, 2023 Consolidated Statements of Financial Position (in thousand euros) December 31, 2023 December 31, 2022 Assets Cash and cash equivalents 70,605 84,225 Short-term investments 21,851 17,260 Trade receivables and others - current 55,557 38,346 Total current assets 148,012 139,831 Intangible assets 416 1,556 Pr |
|
| March 21, 2024 |
Innate Pharma reports Full Year 2023 Financial Results and Business Update EXHIBIT 99.1 Innate Pharma reports Full Year 2023 Financial Results and Business Update • Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress • Licensing of a fourth NK cell engager ANKET® by Sanofi, triggering a €15m payment to Innate; ANKET® partnered asset |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 21, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 21, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 19, 2024 |
Innate Pharma Announces Its Participation To Upcoming Investor Conference EXHIBIT 99.1 Innate Pharma Announces Its Participation To Upcoming Investor Conference Marseille, France, March 19, 2024, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 19, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 14, 2024 |
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results EXHIBIT 99.1 Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results Marseille, France, March 14, 2024, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for t |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 14, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 6, 2024 |
Innate Pharma To Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At Aacr 2024 EXHIBIT 99.1 Innate Pharma To Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At Aacr 2024 •IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 •Preclinical data support further development of IPH45, a differentiated topoisomerase I inhibitor ADC targeting Nectin-4, which is progressing towards the clinic Marseille, France, March 6, 2024, 7:00 AM CET Innate Ph |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 06, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| March 6, 2024 |
EXHIBIT 99.1 First Patient Dosed In Phase 1/2 Study Of Iph6501 In Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma •Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET® platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas. Marseille, France, March 6, 2024, 7:00 AM CET Innate Pharma SA (Euronext Pari |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 6, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 ( |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 21, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| February 21, 2024 |
Innate Pharma Announces Its Participation To Upcoming Investor Conference EXHIBIT 99.1 Innate Pharma Announces Its Participation To Upcoming Investor Conference Marseille, France, February 21, 2024, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below. • Leerink Partners Global Biopharma Confe |
|
| February 6, 2024 |
Up to $75,000,000 American Depositary Shares representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration Statement File No. 333-276164 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 16, 2024) Up to $75,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to the sale of American Depositary Shares, or ADSs, each ADS representing one ordi |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 6, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant’s name into English) Innate Pharma S.A. 117 Avenue de Luminy-BP 30191 13009 Marseille, France + 3 |
|
| February 6, 2024 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $75,000,000. |
|
| February 6, 2024 |
Exhibit 1.1 SALES AGREEMENT April 26, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Innate Pharma S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Marseille under number 424 365 336 (the “Company”), proposes, subject to the terms and conditions state |
|
| January 12, 2024 |
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 Exhibit 99.1 Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024 MARSEILLE, France-(BUSINESS WIRE)-January 12, 2024-Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPH |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of January 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| January 11, 2024 |
Innate Pharma S.A. 17, avenue de Luminy-BP 30191 13009 Marseille, France January 11, 2024 Innate Pharma S.A. 17, avenue de Luminy-BP 30191 13009 Marseille, France January 11, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jimmy McNamara RE: Innate Pharma S.A. Registration Statement on Form F-3 (File No. 333-276164) Acceleration Request Requested Date: January 15, 2024 Requested Tim |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 4, 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0) 4 30 30 30 |
|
| January 4, 2024 |
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board Exhibit 99.1 Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board Two new Executive Board members appointed under recently announced interim CEO, Hervé Brailly Yannis Morel broadens remit to Chief Operating Officer Sonia Quaratino, Chief Medical Officer, appointed to the Executive Board Arvind Sood joins the Company and is appointed Executive Vice President, Pre |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of January 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of January 2024 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| January 4, 2024 |
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program Exhibit 99.1 Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment MARSEILLE, France-(BUSINESS WIRE)-January 4, 2024-Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announc |
|
| December 20, 2023 |
Exhibit 3.1 TRANSLATION FOR INFORMATION PURPOSES INNATE PHARMA SA A corporation with executive board and supervisory board with a share capital of EUR 4 032 971,15 Registered Office: 117, avenue de Luminy, 13009 Marseille 424 365 336 Registry of Trade and Companies of Marseille ARTICLES OF ASSOCIATION (BY-LAWS) Amended by the Executive Board of October 3rd, 2023 TRANSLATION FOR INFORMATION PURPOSE |
|
| December 20, 2023 |
Exhibit 107 Form F-3 (Form Type) INNATE PHARMA S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Equity Ordinary Shares, €0 |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 20, 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 (0) 4 30 30 3 |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
Recent Developments Since June 30, 2023 Exhibit 99.1 Recent Developments Since June 30, 2023 On September 22, 2023, Innate Pharma announced interim efficacy results from the TELLOMAK Phase 2 study in advanced mycosis fungoides according to updated guidelines at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023, that was held September 21-23, 2023 in Leiden, the Netherlands. The data provided clinical activity and favorable s |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of December 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| December 19, 2023 |
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi Exhibit 99.1 Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi Sanofi to exercise one option to license a new ANKET® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization of the program Innate to receive €15m as option exercise payment MARSEILLE, France-(BUSINESS |
|
| December 18, 2023 |
Innate Pharma Announces Leadership Change Exhibit 99.1 Innate Pharma Announces Leadership Change Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chairman of the Supervisory Board, former CEO and company co-founder Hervé Brailly appointed interim CEO Irina Staatz-Granzer, current Vice-Chairwoman of Supervisory Board, appointed Chairwoman of the Supervisory Board MARSEIL |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of December 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| December 11, 2023 |
Exhibit 99.1 Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET) MARSEIL |
|
| December 11, 2023 |
Exhibit 99.1 Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in pati |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of December 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of December 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of November 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| November 27, 2023 |
Innate Pharma to Host Virtual KOL Event on Lacutamab Exhibit 99.1 Innate Pharma to Host Virtual KOL Event on Lacutamab The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual KOL event will be held on Tuesday, December 12, 2023 at |
|
| November 14, 2023 |
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update Exhibit 99.1 Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH Annual Meeting 2023 ASH presentation on SAR443579/IPH6101, a potential first-in-class NKp46/CD16-based NK cell en |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of November 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| November 7, 2023 |
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update Exhibit 99.1 Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update MARSEILLE, France-(BUSINESS WIRE)-November 7, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third q |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of November 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseil |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: [November 3, 2023] Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, France + |
|
| November 3, 2023 |
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 Exhibit 99.1 Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome selected for oral presentation Preliminary monotherapy lacutamab Phase 1b clinical data and pre-clinical combinability data in patients with peripheral T-cel |
|
| October 27, 2023 |
Innate Pharma Announces Its Participation to Upcoming Investor Conferences Exhibit 99.1 Innate Pharma Announces Its Participation to Upcoming Investor Conferences MARSEILLE, France-(BUSINESS WIRE)-October 27, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Conference Eve |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of October 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| October 19, 2023 |
Innate Pharma 2024 Financial Calendar Exhibit 99.1 Innate Pharma 2024 Financial Calendar MARSEILLE, France-(BUSINESS WIRE)-October 19, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024: Publication of revenue for 1Q2024 May 23, 2024: Annual General Shareholders Meeting September 12, 2024 |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of October 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of October 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| October 16, 2023 |
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 Exhibit 99.1 Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation Presentations under the AstraZeneca collaboration include an IPH5201 early lung cancer Trial in Progress poster and monalizumab SCCHN updates MARSEILLE, France-(BUSINESS WIRE)-October 16, 2023-Innate Pharma SA (Eu |
|
| October 10, 2023 |
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023 Exhibit 99.1 Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023 MARSEILLE, France-(BUSINESS WIRE)-October 9, 2023-Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or th |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of October 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of October 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseill |
|
| October 5, 2023 |
Innate Pharma Provides Update on Lacutamab Clinical Program Exhibit 99.1 Innate Pharma Provides Update on Lacutamab Clinical Program Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023 Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023 US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction MARSEILLE, France-(BUSINESS WIRE)-Octobe |
|
| September 22, 2023 |
Exhibit 99.1 Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of September 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marsei |
|
| September 14, 2023 |
INNATE PHARMA REPORTS FIRST HALF 2023 FINANCIAL RESULTS AND BUSINESS UPDATE INNATE PHARMA REPORTS FIRST HALF 2023 FINANCIAL RESULTS AND BUSINESS UPDATE •Phase 1/2 dose escalation safety and preliminary efficacy of ANKET® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded •Exclusive worldwide rights granted to Takeda to res |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of September 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marsei |
|
| September 14, 2023 |
INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2023 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,026,535.85 euros composed of 80,516,622 ordinary shares, and 14,095 preferred shares with a nominal value of 0.05 euros each Registered office: 117, Avenue de Luminy, F-13009 Marseille, France Registered with the Compan |
|
| September 14, 2023 |
Innate Pharma Reports First Half 2023 Financial Results and Business Update Exhibit 99.1 Innate Pharma Reports First Half 2023 Financial Results and Business Update Phase 1/2 dose escalation safety and preliminary efficacy of ANKET® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded Exclusive worldwide rights granted to Ta |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 14, 2023 Commission File Number: 001-39084 Innate Pharma SA (Translation of registrant's name into English) Innate Pharma SA 117 Avenue de Luminy—BP 30191 13009 Marseille, France + 33 |
|
| August 29, 2023 |
Exhibit 99.1 Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update MARSEILLE, France-(BUSINESS WIRE)-August 29, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, det |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of August 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of August 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille |
|
| August 10, 2023 |
Innate Pharma to Participate in Upcoming Investor Conference Exhibit 99.1 Innate Pharma to Participate in Upcoming Investor Conference MARSEILLE, France-(BUSINESS WIRE)-August 10, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming conference: H.C. Wainwright Immune Cell Engager Virtual Conference Event Date: Au |
|
| July 11, 2023 |
Exhibit 99.1 First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of July 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of July 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| July 7, 2023 |
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 Exhibit 99.1 Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 MARSEILLE, France-(BUSINESS WIRE)-July 7, 2023-Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Com |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| June 26, 2023 |
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer Exhibit 99.1 First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE, France-(BUSINESS WIRE)-June 26, 2023-Innate Pharma SA (Euronext P |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| June 16, 2023 |
Exhibit 99.1 Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria Efficacy results presented at the 17th International Conference on Malignant Lymphoma, have been analysed according to updated lymph node involvement classification and confirm clinical activity and favorable safety profile of lacutamab in advanced |
|
| June 12, 2023 |
Exhibit 99.1 Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France-(BUSINESS WIRE)-June 12, 2023-Innate Pharma SA ( |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| June 12, 2023 |
Exhibit 99.1 Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas IPH6501 is progressing towards a Phase 1 clinical trial in 2023 MARSEILLE, Fr |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| June 8, 2023 |
Exhibit 99.1 SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies SAR’579, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi. MARSEILLE, France-(BUSINESS WIRE)-June 8, 2023-Innate Pharma SA (Euron |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| June 7, 2023 |
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 Exhibit 99.1 Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 MARSEILLE, France-(BUSINESS WIRE)-June 7, 2023-Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Com |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of June 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 26, 2023 |
Exhibit 99.1 Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML SAR’579/IPH6101, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data publ |
|
| May 23, 2023 |
Innate Pharma to Participate in Upcoming Investor Conferences Exhibit 99.1 Innate Pharma to Participate in Upcoming Investor Conferences MARSEILLE, France-(BUSINESS WIRE)-May 23, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming conferences: American Society for Clinical Oncology (ASCO) 2023 Annual Meeting Even |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 15, 2023 |
Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress Exhibit 99.1 Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation MARSEILLE, France-(BUSINESS WIRE)-May 15, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Comp |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: for the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 12, 2023 |
Outcome of Innate Pharma’s 2023 Annual General Meeting Exhibit 99.1 Outcome of Innate Pharma’s 2023 Annual General Meeting MARSEILLE, France-(BUSINESS WIRE)-May 12, 2023-Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 12, 2023, in Marseille. All resolutions were voted. A total of 112 votes were cast out of a |
|
| May 10, 2023 |
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update Exhibit 99.1 Innate Pharma Reports First Quarter 2023 Financial Results and Business Update Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to up to $410m in future milestones plus royalties ANKET® assets in collaboration with Sanofi continue to progre |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 9, 2023 |
Number of shares and voting rights of Innate Pharma as of May 1, 2023 Exhibit 99.1 Number of shares and voting rights of Innate Pharma as of May 1, 2023 MARSEILLE, France-(BUSINESS WIRE)-May 9, 2023-Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Compa |
|
| May 9, 2023 |
6-K 1 a53394563.htm INNATE PHARMA S.A. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 A |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of May 2023 Commission File Number: 001-39084 Innate Pharma S.A. (Translation of registrant's name into English) Innate Pharma S.A. 117 Avenue de Luminy—BP 30191 13009 Marseille, F |
